FDA Expands Approval of Oral Agent for Migraine
Atogepant is added to the growing class of CGRP receptor antagonists to prevent episodic and chronic migraine in adults. People living with chronic migraine have a new oral option in the form of atogepant tablets. The FDA has approved an expanded indication of atogepant (Qulipta) to include the prevention of chronic migraine in adults, according to a statement from manufacturer AbbVie.